BioSpace News Archive

f5 Therapeutics Incorporated today announced that they have been selected as a ‘Cool Company’ for the second year in a row.

Ventus Therapeutics , Inc. announced today the appointment of Christine Ha as Chief Financial Officer.

Arrakis Therapeutics announced that company management will participate in the following upcoming investor conferences: Goldman Sachs The New Guard: Privates Leading the Disruption in Healthcare Michael Gilman, Ph.D., Chief Executive Officer of Arrakis, will participate in a panel discussion on Thursday, April 7, 2022 at 11:00 a.m.

Pear Therapeutics, Inc., the leader in developing and commercializing software-based medicines, called prescription digital therapeutics, announced the company will participate in the Credit Suisse The Investor Landscape: Hidden Gems Conference on Thursday, April 7 in New York, NY.

Cipherome, Inc. (“Cipherome”), a Silicon Valley-based, genomic bioinformatics start-up, has joined the American Heart Association Center for Health Technology & Innovation’s (the Center) Innovators’ Network.

Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced financial results for the year ended December 31, 2021 and provided a corporate update on key events since the start of 2021.

Biological Dynamics, Inc., a biotechnology company focused on detecting diseases at the earliest stages, announced participation in a series of global events to discuss industry trends and challenges, and to preview new early-stage cancer detection data based on the company’s novel Verita™ technology.

Kleiner Device Labs today announced that its new KG2TM SurgeTM flow-thru interbody system has been selected as a finalist in the 2022 Medical Design Excellence awards in the Implant and Tissue-Replacement Products category.

Exactech, a developer and producer of innovative implants, instrumentation, and smart technologies for joint replacement surgery, commemorates the 15th anniversary of the launch of the Equinoxe® reverse prosthesis, a groundbreaking implant that has improved clinical outcomes and reduced complication rates1 relative to published meta-analyses2- and has served as the platform for several additional innovations in reverse shoulder arthroplasty.

SciSparc Ltd. announced completion of the previously announced joint venture agreement to focus on the discovery and development of potential drugs for cancers and other life-threatening conditions, MitoCareX Bio Ltd., an Israeli corporation .